摘要
丙型肝炎病毒(HCV)感染的治疗已经有了显著的进展。从耐受性较差的注射治疗治疗率很低,转变为高度有效的耐受良好的口服直接作用的抗病毒疗法,几乎90%的患者得到了治愈。通过识别可被小分子抑制的靶点,直接抗病毒已经被发展为更进一步的理解病毒生命周期。目前为止,已经开发出了蛋白酶抑制剂,非结构性5a抑制剂以及核苷酸和非核苷酸聚合酶抑制剂。这些制剂最初被用于聚乙二醇化干扰素和利巴韦林,并且随后结合不需要使用干扰素。合理的联合用药已经克服了耐药性快速出现的主要挑战,而且每一类第二代药剂均具有改善的安全性和功效特性,药物相互作用较少,副作用很少。本文讨论了直接抗病毒的发展进展以及药物每一级以及将来发展所具有的挑战。
关键词: 直接抗病毒,耐药性,硬化,难治疗,丙型肝炎病毒
Current Drug Targets
Title:Direct-Acting Antivirals for Hepatitis C Virus (HCV): The Progress Continues
Volume: 18 Issue: 7
关键词: 直接抗病毒,耐药性,硬化,难治疗,丙型肝炎病毒
摘要: Treatment for hepatitis C virus (HCV) infection has progressed at remarkable speed. From poorly tolerated injectable therapy with very low cure rates, treatment has moved to highly effective well-tolerated all oral direct-acting antiviral therapies with cure rates above 90% for almost all patients populations. Direct-acting antivirals have developed out of an improved understanding of the viral lifecycle with recognition of targets that could be inhibited by small molecules. To date protease inhibitors, non-structural 5a inhibitors and nucleotide and non-nucleotide polymerase inhibitors have been developed. These agents have been used initially with peginterferon and ribavirin and subsequently in combination without the need for interferon. Rational combinations have overcome the major challenge of rapid emergence of drug resistance and second-generation agents in each class have improved safety and efficacy profiles with fewer drug-drug interactions and very few adverse effects. The progress of direct-acting antiviral development is outlined with a review of each class of agent as well as a discussion of challenges for the future.
Export Options
About this article
Cite this article as:
Direct-Acting Antivirals for Hepatitis C Virus (HCV): The Progress Continues, Current Drug Targets 2017; 18 (7) . https://dx.doi.org/10.2174/1389450116666150825111314
DOI https://dx.doi.org/10.2174/1389450116666150825111314 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
GLP-1/GLP-1RAs: New Options for the Drug Treatment of NAFLD
Current Pharmaceutical Design Interplay of Breast Cancer Resistance Protein (BCRP) and Metabolizing Enzymes
Current Drug Metabolism Carbohydrates: Potential Sweet Tools Against Cancer
Current Medicinal Chemistry Emerging Roles of MicroRNA-22 in Human Disease and Normal Physiology
Current Molecular Medicine Anthocyanins As Modulators of Cell Redox-Dependent Pathways in Non-Communicable Diseases
Current Medicinal Chemistry Cancer “Stemness”- Regulating MicroRNAs: Role, Mechanisms and Therapeutic Potential
Current Drug Targets Statins and Solid Organ Transplantation
Current Pharmaceutical Design ConA-Coated Liposomes as a System to Delivery β-Lapachone to Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Potential Beneficial Effects of Garlic in Oncohematology
Mini-Reviews in Medicinal Chemistry ROCK Inhibitors as Emerging Therapeutic Candidates for Sarcomas
Current Cancer Drug Targets Novel Insights in Molecular Mechanisms of CLL
Current Pharmaceutical Design Inhibitors of the Sphingosine Kinase Pathway as Potential Therapeutics
Current Cancer Drug Targets Blockade of Neoangiogenesis, a New and Promising Technique to Control the Growth of Malignant Tumors and their Metastases
Current Vascular Pharmacology The Power of the Underutilized and Neglected Medicinal Plants and Herbs of the Middle East
Reviews on Recent Clinical Trials DNA Drug Design for Cancer Therapy
Current Pharmaceutical Design Imaging of HER-2 Overexpression in Tumors for Guiding Therapy
Current Pharmaceutical Design Metastatic Cancer Stem Cells: New Molecular Targets for Cancer Therapy
Current Pharmaceutical Biotechnology Signaling Through Rho GTPase Pathway as Viable Drug Target
Current Medicinal Chemistry The Biology of Cholecystokinin and Gastrin Peptides
Current Topics in Medicinal Chemistry Targeting the Nucleotide Metabolism Proteins of the NUDIX Family and SAMHD1 in Cancer
Current Medicinal Chemistry